Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Straight to Phase III: Model-Informed Approach Speeds Depemokimab Clinical Development in Interleukin-5-Driven Diseases.

Clinical pharmacology and therapeutics·2026
Same author

A Combined Model-Based Meta-Analysis of Aggregated and Individual FEV1 Data From Randomized COPD Trials.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis.

Clinical pharmacology and therapeutics·2024
Same author

Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performance.

British journal of clinical pharmacology·2021
Same author

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021
Same author

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021
Same journal

Efficacy and safety of Ensitrelvir in COVID-19 patients: a systematic review and meta-analysis with focus on viral clearance and RNA change.

European journal of clinical pharmacology·2026
Same journal

Comparing National Health Technology Assessment approaches and the new European Joint Clinical Assessment framework: The case of onco-hematological medicines.

European journal of clinical pharmacology·2026
Same journal

The efficacy of letrozole in the medical management of ectopic pregnancy: a systematic review and meta-analysis.

European journal of clinical pharmacology·2026
Same journal

Detection of intravenous drug physicochemical incompatibilities in clinical practice: e-Harvis compared to reference tools.

European journal of clinical pharmacology·2026
Same journal

Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment.

European journal of clinical pharmacology·2026
Same journal

Critical analysis of digitalis glycosides: declining use but increasing poison-center exposure cases for digitoxin.

European journal of clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

Dose finding by concentration-response versus dose-response: a simulation-based comparison.

Alienor Berges1, Chao Chen

  • 1Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Uxbridge, UK.

European Journal of Clinical Pharmacology
|February 7, 2013
PubMed
Summary
This summary is machine-generated.

Concentration-response analysis offers superior precision and a higher success rate for dose finding compared to dose-response analysis. This pharmacokinetic approach optimizes dose selection and reduces sample size requirements in clinical trials.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Experiment Videos

Last Updated: May 14, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Area of Science:

  • Pharmacometrics
  • Clinical Trial Design
  • Pharmacokinetics

Background:

  • Dose finding is critical for optimizing drug efficacy and safety.
  • Traditional dose-response analysis may lack precision in certain scenarios.
  • Pharmacokinetic-pharmacodynamic (PKPD) modeling offers an alternative approach.

Purpose of the Study:

  • To compare the incremental benefit of concentration-response analysis versus dose-response analysis for dose finding.
  • To evaluate the impact on model parameter estimation and confirmatory trial success rates.

Main Methods:

  • Simulated clinical trials using an Emax model across various drug properties and trial designs.
  • Analyzed simulated data using both concentration-response and dose-response modeling.
  • Compared the precision of ED50 estimation and the success rate of dose selection in confirmatory trials.

Main Results:

  • Concentration-response analysis demonstrated up to 90% higher precision in ED50 estimation compared to dose-response analysis.
  • This increased precision led to improved dose selection and up to 20% higher success rates in subsequent trials.
  • The benefits were most pronounced with high inter-subject variability in clearance and low top doses.

Conclusions:

  • Concentration-response analysis provides a more precise and successful approach to dose finding.
  • The findings highlight the value of pharmacokinetic sampling in specific trial contexts.
  • This approach can be customized to assess the utility of PK sampling in various clinical trial situations.